Hope S. Rugo

MD

Breast oncologist

Dr. Hope Rugo is a hematologist-oncologist who specializes in breast cancer treatment. She joined the UCSF Carol Franc Buck Breast Care Center after a decade at UCSF Medical Center, where she worked in bone marrow transplantation for a variety of diseases, including breast cancer.

Rugo is co-director of UCSF's breast cancer clinical trials program. She is the principal investigator for several clinical trials of potential new therapies. She is also an investigator with the Bay Area's SPORE (Specialized Programs of Research Excellence) on breast cancer. The National Cancer Institute established SPORE to foster collaborative, interdisciplinary cancer research.

  • Education

    University of Pennsylvania School of Medicine, 1984

  • Residencies

    UCSF Medical Center, Internal Medicine, 1987

  • Fellowships

    UCSF Medical Center, Hematology, 1990

    UCSF Medical Center, Oncology, 1995

  • Board Certifications

    Internal Medicine, American Board of Internal Medicine

    Medical Oncology, American Board of Internal Medicine

  • Academic Title

    Professor

  • Languages

    French

    Spanish

Conditions I specialize in

Where I see patients (1)

    My reviews

    4.9

    Overall Experience
    255 Ratings
    About our process
    Mar 01, 2023
    Very good
    Feb 18, 2023
    I am lucky to have Dr Rugo in my corner and I refer many people with metastatic breast cancer to her for a second opinion
    Feb 17, 2023
    Based upon my experience "Excellent" would be more descriptive than "Very Good
    Feb 16, 2023
    Sometimes the dialogue went faster than I was able to keep up with. For me it was new ground (due to poor care and Communication by a previous provider) even though my diagnosis was not.
    Feb 02, 2023
    Dr. Rugo is so professional. I really feel she listens and wants the best for her patients. I am so thankful to have her for an oncologist. I always feel better after my clinic visit.
    Feb 01, 2023
    Dr Rugo is fantastic! She is brilliant and listens carefully to my input. I feel so blessed to have her as my oncologist.
    Jan 16, 2023
    My only complaint is with scheduling an appointment. I had difficulty getting through to the scheduler. I had to wait quite awhile for a follow up appointment after having a biopsy. The long wait and lack of communication made me anxious. I just would have appreciated a follow up call or message on MyChart letting me know they are working on scheduling an appointment. This was over the busy holiday so I'm sure this could have contributed but it does seem to take some time to get questioned answered on MyChart.
    Nov 30, 2022
    Dr Rugo is excellent. She is exceptionally intelligent spends time with me exploring treatment options is compassionate and caring and always makes me feel better when I leave my meeting with her.
    Nov 30, 2022
    Dr. Rugo was excellent in her discussion of the issues and her compassion.
    Nov 16, 2022
    Dr Rugo is the expert I will have her to take the lead for my care.
    Nov 09, 2022
    Dr Rugo is extremely brilliant and compassionate. I am lucky beyond words to have her as my oncologist.
    Oct 07, 2022
    Dr. Rugo was very calm and spoke very professionally. She discussed the medication I am taking for cancer and any concerns regarding side effects. She discussed medication that I use to prevent nausea while taking Versenio.
    Sep 16, 2022
    The care provider was rude and spoke to me very gruffly. If this doesn't stop Im going elsewhere for breast cancer care.
    Sep 14, 2022
    I am in good hands
    Jul 15, 2022
    Doctor Rugo is outstanding in her care concern attention communications and expertise.
    Jul 11, 2022
    Just Dr. Rugo was constantly on volate texting about other patients during my visit. Every time I tired to ask questions it was Interrupted by her texting. I felt like my concerns were In her while In the room. I forgot I had other questions to ask because of that after I left. Felt like I was being condone at times because I had reached out on my chart but she says I never did reach out but I told her that that support nurses said they asked you.
    Apr 13, 2022
    This provider is exceptionally good. She listens attentively and is very smart. I am extremely lucky to have her as my care provider.
    Apr 09, 2022
    LOVE DR RUGO AND HER STAFF!!!
    Mar 31, 2022
    Great Doctor! Please work on time management- if possible
    Mar 05, 2022
    I am very lucky and feel very secure with Dr Rugo
    Mar 02, 2022
    Good
    Feb 28, 2022
    Still exploring treatment options and test results. No follow up care can be provided at this time as my case is still in the exploratory phase
    Feb 16, 2022
    Dr Rugo is best!
    Feb 13, 2022
    I wished for a few minutes more
    Jan 13, 2022
    As always I am impressed with Dr. Rugo's ability to remember the salient details from previous visits thus insuring continuity of care.
    Dec 16, 2021
    Blessed to have Dr. Rugo taking care of my situation. I was hoping for a little more time with her and less time waiting and with another MD.
    Nov 25, 2021
    I have already recommended a friend in CA to get a second opinion from Dr. Rugo. I am convinced that she is best breast cancer expert in the area.
    Nov 03, 2021
    She really dominates her field of knowledge.
    Oct 20, 2021
    Dr. Rugo is so conscientious about her patients and our care. She leaves no stone unturned and I'm so grateful for her thoroughness.
    Jul 13, 2021
    I was so impressed with the depth and breadth of information my doctor shared with me. I am terribly happy with my experience.
    Jun 21, 2021
    good and challenging experience
    Jun 19, 2021
    Hope Rugo is an unbelievable clinician. Her knowledge and her compassion are combined to provide a pathway for a patient to make the best choice as possible
    Jun 16, 2021
    I am blessed to be under Dr. Rugo's care
    Jun 03, 2021
    Great listener. The other doctor was very sweet and took notes for me during the visit. It was a lot of information so I really appreciated having the notes to review.

    Selected research

    Decorative Caduceus

    T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk H...

    A Kaplan-Meier method will be used to estimate the survival curves and a stratified log-rank test will be used to compare the invasive disease-free survival (iDFS) of the two arms. A stratified Cox model will be used to estimate t...

    Recruiting

    Decorative Caduceus

    A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Can...

    IDFS excluding second non-breast primary invasive cancers

    Recruiting

    Decorative Caduceus

    Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello...

    Dose-limiting toxicity as described in the protocol that is not related to disease progression, intercurrent illness or concomitant medications and that, despite optimal therapeutic intervention, meets protocol-defined criteria.

    Recruiting

    Decorative Caduceus

    ATEMPT 2.0: Adjuvant T-DM1 vs TH

    Compare the incidence of clinically relevant toxicities (CRT) in patients with Stage I HER2-positive breast cancer treated with trastuzumab emtansine followed by trastuzumab SC to the incidence in those treated with paclitaxel in ...

    Recruiting

    Decorative Caduceus

    Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo...

    The outcome measure of the study is IDFS, defined by the STEEP system as the first occurrence of the time from the date of randomization to the date of first invasive disease recurrence (local, regional or distant), the date of se...

    Recruiting

    Decorative Caduceus

    Study of PF-07248144 in Advanced or Metastatic Solid Tumors

    Dose-limiting toxicities (DLTs)

    Recruiting

    Decorative Caduceus

    A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants W...

    Recruiting

    Decorative Caduceus

    Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

    Clearance of tumor cfDNA after 18 weeks, it will be tested using a one-sided one-sample binomial exact test (alpha 5%) against a null hypothesis value of 7% false negatives.

    Recruiting

    Decorative Caduceus

    Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Br...

    Progression-Free Survival (PFS) is defined as the time from the first dose of study treatment to the date of disease progression as assessed by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or death due to any cause, ...

    Recruiting

    Decorative Caduceus

    Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metas...

    A patient is said to have derived clinical benefit rate at the 6 month time point if the patient's disease meets the Response Evaluation Criteria in Solid Tumors (RECIST) for complete response (CR), partial response (PR), or stabl...

    Recruiting

    Contact me

    Providers on my team

    Share